ESANEX
Esanex is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors. SNX-5422, created from a novel chemical scaffold that is unique in the Hsp90 field, has shown outstanding pre-clinical activity in a number of tumor models and is currently completing Phase 1 trials.
ESANEX
Industry:
Biotechnology Developer Platform Information Technology
Founded:
2011-01-01
Address:
Indianapolis, Indiana, United States
Country:
United States
Status:
Closed
Total Funding:
15 M USD
Investors List
Intersouth Partners
Intersouth Partners investment in Venture Round - Esanex